Bluebird Bio (BLUE) announced that it will proceed with a 1-for-20 reverse stock split of the company’s common stock following approval by both its Board of Directors and BLUE stockholders at ...

Shares of bluebird bio BLUE have lost 59.9% in the year so far, underperforming the industry’s 16.4% decline. Zacks Investment Research Image Source: Zacks Investment Research Devoid of a ...

Shares of bluebird bio BLUE have increased by 25.6% in a month compared with the industry’s growth of 0.2%. Last month, bluebird posted better-than-expected results in the third quarter. It ...

Fintel reports that on November 15, 2024, B of A Securities downgraded their outlook for bluebird bio (NasdaqGS:BLUE) from Buy to Neutral. Analyst Price Forecast Suggests 775.17% Upside As of ...

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where bluebird bio, Inc. (NASDAQ:BLUE) stands ...

bluebird bio Inc ( BLUE) has moved higher as of late, but there could definitely be trouble on the horizon for this company. That is because BLUE is now in overbought territory with an RSI value ...

In an unscheduled price adjustment by the Public Utilities Board, the cost of home heating oil has risen by nearly 20 cents per litre. In a media release the PUB said the rise in price is "due to ...

May 20, 2025. Preview this article 1 min. BlueSphere Bio's new chief scientific officer brings decades of experience from big pharma to the Pittsburgh startup's innovative T-cell therapy programs.

Robert W. Baird analyst Jack Allen maintained a Buy rating on Bluebird Bio (BLUE – Research Report) on August 9 and set a price target of $10.00. The company’s shares opened today at $3.32 ...